Shanghai?Biobond?Pharmaceutical?Co.?Ltd was registered and established in June 2013, located in the eastern area of Zhangjiang High tech Park (National Medical Device Park) in Shanghai. Invested by several senior Chinese pharmacologists, it was founded based on the first-class research conditions and screening platform of the Chinese Academy of Sciences. The company is mainly committed to the research of new drugs in the fields of nerve pain, anti-tumor, and drug-resistant new antibiotics. The main management personnel of the company have rich company management experience, profound background in new drug research and development technology, and rich experience in new drug research and development; The main research and development team consists of professionals in synthesis, pharmacology, formulation, analysis, and other fields. Currently, there is one academician, two professors, multiple doctoral and master's degrees. The company's main business direction is "overall solution solution" for generic drug research, technical public relations, and new drug research.
CAS：763113-22-0
CAS：1108743-60-7
CAS：218301-22-5
CAS：59878-57-8
CAS：13754-38-6
